|
2026 Journal Article Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapyThunold, Solfrid, Hernes, Eivor, Gyland Mikalsen, Lars Tore, Farooqi, Saima, Öjlert, Åsa Kristina, Francis, Roslyn J, Nowak, Anna K, Szejniuk, Weronika Maria, Nielsen, Søren Steen, Cedres, Susana, Perdigo, Marc Simo, Sørensen, Jens Benn, Meltzer, Carin, Helland, Åslaug, Malinen, Eirik and Haakensen, Vilde Drageset (2026). Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy. EJNMMI Research, 16 (1) 132. doi: 10.1186/s13550-026-01469-x |
|
2026 Journal Article Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Sartor, Oliver, Morris, Michael J., Subramaniam, Shalini, Crumbaker, Megan, Ayati, Narjess, Chen, Jeffrey, Herrmann, Ken, Gafita, Andrei, Swiha, Mina, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Ho, Bao, Khan, Sobia, Tan, Thean Hsiang, Bills, Madison, Nguyen, Andrew, Thein, Thida, Sidhom, George, Wong, Keith, Martin, Andrew James, Hofman, Michael S., Sandhu, Shahneen ... Davis, Ian D. (2026). Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901). European Urology. doi: 10.1016/j.eururo.2026.03.026 |
|
2026 Journal Article Impact of [18F]FET-PET on MRI-Based Radiotherapy Target Volumes in Newly Diagnosed Glioblastoma:Results from the FET-PET in Glioblastoma (FIG) Study TROG 18.06Koh, E-S, Francis, R J, Ninatti, G, Ruisi, I, Ebert, M A, Lau, E, Whitehead, A, Descallar, J, Barnes, E H, Lee, S T, Thomas, E L, Pinkham, M B, Back, M, Ng, S P, Bucknell, N, Gan, H K, Cook, O, Dykyj, R, Moore, A, Porter, S, Banyer, Patricia, Scott, F E, Bailey, D L, Barry, N, Akhurst, T, Alipour, R, Bece, A, Bettingdon, C, Beuzeville, S ... Scott, A M (2026). Impact of [18F]FET-PET on MRI-Based Radiotherapy Target Volumes in Newly Diagnosed Glioblastoma:Results from the FET-PET in Glioblastoma (FIG) Study TROG 18.06. Neuro-Oncology noag229. doi: 10.1093/neuonc/noag229 |
|
2026 Journal Article Peri-coronary inflammation and coronary microcalcification activity in subjects with diabetes mellitus; a cross-sectional analysisSmith, Brodie, Bellinge, Brynn, Francis, Roslyn J., Parry, Reece, Lee, Sing Ching, Bellinge, Jamie W. and Schultz, Carl J. (2026). Peri-coronary inflammation and coronary microcalcification activity in subjects with diabetes mellitus; a cross-sectional analysis. Journal of Diabetes and its Complications, 40 (5) 109316. doi: 10.1016/j.jdiacomp.2026.109316 |
|
2026 Journal Article Analysis of the impact of female sex and muscle mass on serum creatinine and waitlist priority for liver transplantationGupta, Shivangi, Jeffrey, Angus W., Wang, Zhengyi, Adams, Leon A., Garas, George, Macquillan, Gerry, Wallace, Michael C., Smith, Briohny, Lim, Wai H., Francis, Ros, Welman, Christopher J. and Jeffrey, Gary P. (2026). Analysis of the impact of female sex and muscle mass on serum creatinine and waitlist priority for liver transplantation. Liver Transplantation, 32 (5), 717-725. doi: 10.1097/LVT.0000000000000747 |
|
2026 Journal Article Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialEmmett, Louise, Swiha, Mina, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn, Goh, Jeffrey, Pattison, David, Pathmanandavel, Sarennya, Hope, Thomas, Ayati, Narjess, Hofman, Michael, Sandhu, Shahneen, Niu, Claire, Martin, Andrew, Thomas, Hayley, Stockler, Martin and Davis, Ian (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nature Cancer, 7, 622-630. doi: 10.1038/s43018-026-01140-3 |
|
2026 Journal Article 177 Lu-PSMA-617 SPECT/CT for early prediction of overall survival in participants with metastatic castration-resistant prostate cancerAyati, Narjess, Papa, Nathan, Crumbaker, Megan, Subramaniam, Shalini, Joshua, Anthony M., Alipour, Ramin, Iravani, Amir, Askari, Emran, Khan, Sobia, Yadav, Surekha, Eiber, Matthias, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Nguyen, Andrew, Hofman, Michael S., Sandhu, Shahneen, Hioki, Takanori, van Oorschodt, Julian C. J., Devitt, Katrina, Willowson, Kathy, Sharma, Shikha, Stancu, Alexandru, Chauvie, Stephane ... on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319 (1) e252672, e252672. doi: 10.1148/radiol.252672 |
|
2026 Journal Article Baseline nodal status on 68Ga-PSMA-11 positron emission tomography/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trialHofman, Michael S., Kasivisvanathan, Veeru, Link, Emma, Buteau, James, Roberts, Matthew J., Francis, Roslyn J., Tang, Colin, Vela, Ian, Thomas, Paul, Rutherford, Natalie, Martin, Jarad M., Frydenberg, Mark, Shakher, Ramdave, Wong, Lih-Ming, Taubman, Kim, Ting Lee, Sze, Hsiao, Edward, Roach, Paul, Nottage, Michelle, Kirkwood, Ian, Hayne, Dickon, Iravani, Amir, Williams, Scott, O'Brien, Jonathan, Lawrentschuk, Nathan and Murphy, Declan G. (2026). Baseline nodal status on 68Ga-PSMA-11 positron emission tomography/computed tomography in men with intermediate- to high-risk prostate cancer is prognostic for treatment failure: follow-up of the proPSMA trial. European Urology Oncology, 9 (2), 422-429. doi: 10.1016/j.euo.2024.11.006 |
|
2026 Journal Article Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerMunzur, Aslı D., Herberts, Cameron, Kwan, Edmond M., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Zhang, Alison Y., Williams, Scott G., Bernales, Cecily Q., Donnellan, Gráinne, Koudjanian, Melissa, Parekh, Karan, Bacon, Jack V. W., Karsan, Aly, Azad, Arun A., Davis, Ian D., Hofman, Michael S. and Wyatt, Alexander W. (2026). Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. Clinical Cancer Research, 32 (13). doi: 10.1158/1078-0432.ccr-25-4001 |
|
2026 Journal Article RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancerMolin, Kaylee, Ong, Jeremy S. L., Werf, Steven Van Der, Francis, Roslyn J., Hassan, Ghulam Mubashar, Ebert, Martin A. and Kendrick, Jake (2026). RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53 (4), 2234-2244. doi: 10.1007/s00259-025-07592-6 |
|
2026 Journal Article SUBDUE-3: SUB-urothelial DUrvalumab-89zirconium injEction; a phase 0 biodistribution study protocolKeane, Kevin G., Gauci, Richard, Francis, Roslyn J., Scott, Andrew M., Hawks, Cynthia, Inderjeeth, Andrisha-Jade, Davis, Ian D., Lim, Jayne, Redfern, Andrew and Hayne, Dickon (2026). SUBDUE-3: SUB-urothelial DUrvalumab-89zirconium injEction; a phase 0 biodistribution study protocol. BJU International, 138 (S2) bju.70153, S26-S29. doi: 10.1111/bju.70153 |
|
2026 Journal Article Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular riskVerma, Shipra, Lan, Nick S. R., Espedal, Heidi, Ong, Jeremy, Roy, Ambuj, Ahmad, Adilah, Ali, Kamar, Ward, Natalie C., Patel, Sanjay, Parizel, Paul M., Francis, Roslyn J. and Dwivedi, Girish (2026). Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk. European Journal of Nuclear Medicine and Molecular Imaging, 53 (5), 3246-3257. doi: 10.1007/s00259-025-07656-7 |
|
2026 Journal Article Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test–retest trialKendrick, Jake, Francis, Roslyn J., Hassan, Ghulam Mubashar, Ong, Jeremy S. L., Jeraj, Robert, Barry, Nathaniel and Ebert, Martin A. (2026). Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test–retest trial. Radiologia Medica, 131 (2), 320-331. doi: 10.1007/s11547-025-02137-1 |
|
2025 Conference Publication HearCog Trial‐ Findings from FDG‐PETEspedal, Heidi, Jayakody, Dona M. P., Polpo, Adriano, Andrew, Ford H., Flicker, Leon, Almeida, Osvaldo P. and Francis, Roslyn (2025). HearCog Trial‐ Findings from FDG‐PET. Alzheimer's Association International Conference (AAIC) 2025, Toronto, Canada, 27-31 July 2025. Hoboken, NJ United States: John Wiley & Sons. doi: 10.1002/alz70856_100129 |
|
2025 Conference Publication Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trialLewis, Katharine, Blombery, Piers, Sungala, Nagendra Prasad, Giri, Pratyush, Marconi, Tamara, Cochrane, Tara, Francis, Roslyn, Lee, Sze-Ting, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Keane, Colm, Hunter, Sally, Burgess, Melinda, Kannan, Sushmitha, Carlson, Julia, Walia, Mannu, Butcher, Belinda and Cheah, Chan (2025). Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial. 67th American Society of Hematology Annual Meeting and Exposition, Orlando, FL United States, 6–9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-1016 |
|
2025 Conference Publication New 18F and 68Ga tracers for PET myocardial perfusion imagingIoppolo, Joseph, Morandeau, Laurence, Hill, Leila, Rendina, Louis, Francis, Roslyn and Sadler, Alexander (2025). New 18F and 68Ga tracers for PET myocardial perfusion imaging. International Symposium on Radiopharmaceutical Sciences iSRS 2025, Gold Coast, QLD, Australia, 11-15 May 2025. Philadelphia, PA, United States: Elsevier. doi: 10.1016/j.nucmedbio.2025.109186 |
|
2025 Journal Article ARTnet perspectives and contributions to theranosticsFrancis, Roslyn J., Bailey, Dale L., Willowson, Kathy, Latter, Melissa J., Chappell, Bridget, McGill, George, Hofman, Michael S., Emmett, Louise and Scott, Andrew M. (2025). ARTnet perspectives and contributions to theranostics. World Journal of Nuclear Medicine, 24 (3), 231-237. doi: 10.1055/s-0045-1812309 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D, Stockler, Martin R and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Journal Article Fluorodeoxyglucose positron emission tomography detects persistent arterial inflammation after symptomatic COVID-19Espedal, Heidi, Verma, Shipra, Roy, Ambuj, Lan, Nick S.R., Mohd, Sheeraz, Bartlett, Benjamin, Ali, Kamar, Ward, Natalie C., Ebert, Martin A., Chan, Dick C., Watts, Gerald F., Dwivedi, Girish and Francis, Roslyn J. (2025). Fluorodeoxyglucose positron emission tomography detects persistent arterial inflammation after symptomatic COVID-19. Heart Lung and Circulation, 34 (9), 969-976. doi: 10.1016/j.hlc.2025.03.005 |
|
2025 Conference Publication 18F-FDG PET/CT Reveals Persistent Lung and Vascular Inflammation in Mild-to-Moderate COVID-19 Compared to Controls: Implications for Cardiovascular RiskVerma, S., Lan, N., Espedal, H., Ong, J., Roy, A., Ahmad, A., Ali, K., Ward, N., Patel, S., Parizel, P., Francis, R. and Dwivedi, G. (2025). 18F-FDG PET/CT Reveals Persistent Lung and Vascular Inflammation in Mild-to-Moderate COVID-19 Compared to Controls: Implications for Cardiovascular Risk. 73rd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Sydney, NSW Australia, 14-17 August 2025. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2025.06.077 |
